Clinical Trial Update: CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma

View source ↗

Summary

A clinical trial conducted at Henan Cancer Hospital is evaluating a CD20 monoclonal antibody-based first-line therapy for treatment-naive marginal zone B-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone B-cell Lymphoma

Drugs mentioned

• CD20 monoclonal antibody-based first-line therapy

Snippet

Sponsor: Henan Cancer Hospital | Conditions: MZL | Status: NOT_YET_RECRUITING